Table 2.
Clinical, CVD, and HIV Characteristics (N = 130)
| Mean (SD) | n (%) | |
|---|---|---|
| Body Mass Index (BMI) | 26.7 (5.5) | |
| Years since HIV diagnosis | 14.6 (7.9) | |
| Hepatitis C antibody positive | 63 (48.5) | |
| CVD Risk Factors | ||
| Total Cholesterol | 170 (36) | |
| LDL | 97 (33) | |
| HDL | 44 (17) | |
| Framingham Risk Score | 7.9 (6.0) | |
| Fasting glucose | 96 (25) | |
| Type 2 Diabetes | 13 (10) | |
| Current smoker | 73 (56.2) | |
| On lipid-lowering medication | 11 (8.5) | |
| On daily aspirin | 9 (7.0) | |
| Hypertension Stage | ||
| Normal | 43 (33.1) | |
| Pre-Hypertension | 63 (48.5) | |
| Stage 1 Hypertension | 22 (16.9) | |
| Stage 2 Hypertension | 2 (1.5) | |
| HIV Characteristics | ||
| CD4+Tcell, cells/mm3 | 546 (292) | |
| Nadir CD4+T cells/mm3 | 195 (142) | |
| HIV viral load, undetectable | 93 (71.5) | |
| Type of ART Regimen | ||
| NNRTI-based | 47 (36.2) | |
| PI-based | 54 (41.5) | |
| NRTI-sparing | 5 (3.8) | |
| Other type of regimen | 8 (6.2) | |
| Not on ART | 16 (12.3) | |
Note. CVD = cardiovascular disease; LDL = low density lipoproteins; HDL = high density lipoproteins; NNRTI = non-nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; NRTI = nucleoside reverse transcriptase inhibitor; ART = antiretroviral therapy.